2nd Annual Pharmaceutical Portfolio Strategy and Management Conference

May 13-14, 2019 | Philadelphia, PA

Renaissance Philadelphia Airport Hotel

Download AgendaRegister Now

DAY TWO | TUESDAY, MAY 14TH

8:00 REGISTRATION & WELCOME COFFEE

8:30 CASE STUDY: WORKING TOWARD ALIGNMENT OF PORTFOLIO STRATEGY WITH BROADER CORPORATE VISION
Although it may seem relatively simple for a small biopharma organization focused on a small number of programs to pull corporate vision through to portfolio operations, the pressures and forces characteristic to small biopharma organizations can actually make this alignment more difficult and create a significant disconnect between corporate vision and portfolio outputs. To avoid this trap, portfolio operations must be continuously aligned with corporate leadership’s vision to ensure strategic fit of new products. Approaches will be shared to address this challenge to best serve patients and stakeholders both within small-scale biopharma companies as well as within larger companies that are considering relationships with smaller organizations.

  • Defining a strong corporate vision within small companies
  • Challenges in executing vision on a small scale
  • Aligning portfolio operations to reach a “right-sized” approach

Chris Dandrea, VP, Global Program Management, UNIQURE

 

ALIGNING R&D PORTFOLIO BUDGETS WITH COMMERCIAL & OPERATIONAL RESOURCES FOR OPTIMIZED EFFICIENCY
In a setting with finite resources, pharmaceutical portfolio strategy and management executives are continually striving to leverage assets both financial and operational including materials and staff to ensure an alignment between R&D priorities and current commercial products. Striking the most appropriate balance, which mitigates risks while at the same time ensuring new products enter the market in an expeditious manner is incredibly challenging and requires detailed insight into multiple projects at varying stages across the lifecycle. Multiple case studies, highlighting the strategic aspects of R&D budgeting against the operational management of assets will ensure participants gain insights into the importance of internal alignment to optimize resources.

 

9:15 DEVELOPING & DEPLOYING A GOVERNANCE MODEL TO ACCELERATE STRATEGY IMPLEMENTATION ACROSS PORTFOLIO
Governance models are necessary for the effective alignment of projects and programs to the business strategy and must be implemented and maintained despite a changing and dynamic environment. Aligning the portfolio to the commercial needs and R&D capabilities yields increased program effectiveness and drives the portfolio’s ultimate value.

  • Exploring the definition of an effective governance model
  • Impact of governance models on accelerated development
  • Measuring the success of a particular governance approach
  • Evolving the model to reflect the growth and change in the organization

Chuck Vecoli, Director Strategy, Portfolio and Program Management, ALEXION PHARMACEUTICALS

 

9:45 CASE STUDY 2: OPERATIONAL ALIGNMENT OF R&D AND COMMERCIAL RESOURCES

  • Optimizing financial, material & human resources
    • Required resources for product research
    • Granular analysis of resources & cost
  • Prioritization of projects based on risk profiles
    • Synchronizing R&D costs & revenue
    • Frequency of budget alignment
  • Balancing short & long term goals against resources

Suman Dasgupta, Senior Manager, Portfolio Analytics, ROCHE SEQUENCING SOLUTIONS

 

10:15 COFFEE & NETWORKING BREAK

 

10:45 WORKSHOP: CALCULATING COMMERCIAL POTENTIAL OF NEW PHARMACEUTICAL PRODUCT CANDIDATES
Within the pharmaceutical industry, portfolio strategy and management professionals alike continuously strive for more effective methods of measuring commercial potential, seeking to balance calculations of revenue, cost, timing, and risk to ultimately arrive at net present value. Additionally, multiple interpretations of each factor are employed, resulting in calculation variations across organizations and individuals. Industry members will benefit from this hands-on opportunity to share techniques for reaching the most accurate calculation of commercial potential.

Neal Mitra, Senior Director, Head of Global Portfolio Management, Oncology
EMD SERONO/MERCK KGaA

 

11:45 PANEL: POSITIONING PORTFOLIO RECOMMENDATIONS FOR OPTIMAL PHARMACEUTICAL EXECUTIVE LEADERSHIP BUY-IN

  • Efficiently communicating risk calculations
  • Identifying useful commercial data insights
  • Clearly condensing portfolio analyses
  • Achieving alignment with financial leadership

Dean Santoro, BIOGEN

Sebastian Liehr, SANTEN

Grace You, MERCK KGAA

Kasia Hopek, GILEAD SCIENCES

Bill Reid, BRISTOL-MYERS SQUIBB

 

12:30 LUNCHEON FOR ALL PARTICIPANTS

 

DATA ANALYTICS MODULE: OPERATIONAL BEST PRACTICES & SUPPORTING STRATEGIC PORTFOLIO OPTIMIZATION

1:30 MASTERCLASS: LEVERAGE OF DATA ANALYTICS FOR STRATEGIC PORTFOLIO DECISION MAKING

  • Use of data in highlighting potential risks
  • Quantifying risks in portfolio decisions
  • Rapid data collection for checkpoints
  • Balancing data against human intuition

Matthew Kokkonen, Director, Portfolio & Governance, CSL BEHRING

 

2:15 EXCHANGE GROUPS: DATA ANALYTICS TOOLS & STRATEGIES TO MASTER PORTFOLIO OPTIMIZATION
In small group discussions, participants will have the opportunity to dive deeper into one of a variety of tools or strategies surrounding the use of data in portfolio decision making, operational management and strategy, providing a platform for peer-to-peer exchange on experiences, challenges and best practices. With a focus on practical solutions, the small groups will highlight the opportunities which exist in leveraging high levels of data to ultimately support the corporate goals.

GROUP 1: Data Visualization – Suman Dasgupta, ROCHE SEQUENCING SOLUTIONS

GROUP 2: Machine Learning / AI – Christy King, JANSSEN

GROUP 3: Data Mining – Geoff Stamper, BRISTOL-MYERS SQUIBB

GROUP 4: Single-Source Data – Kinny Trivedi, JANSSEN

 

2:45 COFFEE & NETWORKING BREAK

 

MAINTAINING DATA INTEGRITY & GOVERNANCE FRAMEWORKS TO SUPPORT PORTFOLIO ANALYTICS

3:15 PART 1 – CASE STUDY: REAL-LIFE DATA INTEGRITY CHALLENGES & SOLUTIONS
Although vast volumes of data surrounding product candidates is generated by pharmaceutical corporations, rolling up the data into a format which becomes usable requires strict data integrity, secured through governance frameworks utilized by all data collection points throughout the organization in a harmonized and effective manner. Varied technologies supporting data collection and the evolution of data analytics frameworks have resulted in challenges surrounding data integrity which ultimately hinder decision making. In order to support the optimal decision regarding overall portfolios as well as individual product candidates, pharmaceutical organizations must ensure data is of the highest accuracy through strategies such as the use of single-source data.

Melanie Ball, Associate Director, Market Analysis & Strategy, Portfolio Analytics, GENENTECH

 

4:00 PART 2 – EXCHANGE GROUPS: DISTINCT PERSPECTIVES ON ENHANCING DATA INTEGRITY & GOVERNANCE
Data accuracy is a crucial area of focus for both portfolio managers and portfolio strategists in the industry, with professionals in each discipline dependent upon the other for upholding agreed-upon standards. However, the ways in which questions of data integrity and governance must be approached differ according to the perspective of the individual’s role in the process. This breakout session will allow delegates to share solutions to mutual challenges among peers addressing data veracity from similar viewpoints.

  • GROUP 1: Strategic portfolio leaders
  • GROUP 2: Operational portfolio teams

Matthew Kokkonen, Director, Portfolio & Governance, CSL BEHRING

 

4:30 CLOSING REMARKS & CONFERENCE CONCLUSION

Share This